Objective:To explore the therapeutic effect of Shensong Yangxin capsule on patients with paroxysmal at-rial fibrillation(PAF)and its effect on serum levels of carbohydrate antigen 125(CA125),brain natriuretic peptide(BNP)and homocysteine(Hcy).Methods:A total of 106 PAF patients treated in Anhui No.2 Provincial People's Hospital between January 2020 and December 2020 were selected,randomly divided into control group(n=53)and observation group(n=53).The patients in the control group were treated with amiodarone hydrochloride tablets combined with placebo,and the patients in the observation group were treated with amiodarone hydrochloride tab-lets combined with Shensong Yangxin capsule.After 3-month treatment,the clinical efficacy,serum CA125,BNP,Hcy levels,P wave dispersion and atrial fibrillation attack frequency were compared between the two groups.Results:The total effective rate in the observation group was significantly higher than that of control group(94.34％vs.77.36％,P=0.012).Compared with control group after treatment,observation group showed a sig-nificant reduction in serum levels of CA125[(48.27±5.31)U/ml vs.(35.03±6.51)U/ml],BNP[(223.27±53.25)pg/ml vs.(156.03±33.86)pg/ml],Hcy[(14.34±3.72)μmol/L vs.(12.67±3.13)μmol/L],P wave dispersion[(46.03±3.52)ms vs.(35.27±3.31)ms]and atrial fibrillation attack frequency[(8.65±2.13)times/month vs.(4.25±1.02)times/month](P＜0.05 or＜0.01).Conclusion:Shensong Yangxin capsule can significantly improve the clinical efficacy,reduce serum levels of CA125,BNP and Hcy,and reduce atrial fibrilla-tion attack frequency in patients with paroxysmal atrial fibrillation,which is worthy of promotion and application.
NETL
NSTL
万方数据
